An anti-factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A.

CONCLUSION: Emicizumab improved ex-vivo coagulation potential in plasma from AHA patients. PMID: 31984625 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31984625?dopt=Abstract

Source: Thrombosis and Haemostasis - January 25, 2020 Category: Hematology Authors: Takeyama M, Nogami K, Matsumoto T, Noguchi-Sasaki M, Kitazawa T, Shima M Tags: J Thromb Haemost Source Type: research